首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2015年 2期 自身免疫性肝病 => 综述 =>凝血因子ⅡG20210A突变在布..
凝血因子ⅡG20210A突变在布加综合征和门静脉血栓形成中的意义
Significance of factor II G20210A mutation in Budd-Chiari syndrome and portal vein thrombosis
文章发布日期:2015年02月13日  来源:  作者: 张文文, 祁兴顺, 郭晓钟  点击次数:1726次  下载次数:403次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:大量研究发现凝血因子ⅡG20210A突变与布加综合征和门静脉血栓形成有关。介绍了凝血因子Ⅱ及凝血因子ⅡG20210A突变,回顾了有关凝血因子ⅡG20210A突变对血栓形成的影响,并对凝血因子ⅡG20210A突变的患病率进行了分析,着重总结了凝血因子ⅡG20210A突变与门静脉血栓和布加综合征的关系。认为凝血因子ⅡG20210A突变在一定程度上增加了门静脉血栓和布加综合征的风险。但凝血因子ⅡG20210A突变在中国患者中的患病率极低,其也许并不足以作为中国门静脉血栓和布加综合征的病因。
【Abstract】:Budd-Chiari syndrome (BCS) is characterized by the hepatic outflow obstruction from the small hepatic vein to the superior hepatic inferior vena cava. Portal vein thrombosis (PVT) refers to the development of thrombosis in the main portal vein, with or without thrombosis in the superior mesenteric or splenic vein. A large number of studies have shown that prothrombin (factor II, F2) G20210A mutation is related to BCS and PVT. F2 and its G20210A mutation are introduced, the effect of F2 G20210A mutation on thrombosis is reviewed, and the prevalence of F2 G20210A mutation in China is analyzed. An attempt is made to focus on the association of F2 G20210A mutation with PVT and BCS. It is believed that F2 G20210A mutation to some extent increases the risk for PVT and BCS. However, the prevalence of F2 G20210A mutation is extremely low in the Chinese population. Thus, this mutation may not be regarded as the cause of PVT and BCS in China.
【关键字】:Budd-Chiari综合征;门静脉;静脉血栓形成;凝血酶原;突变;综述
【Key words】:Budd-Chiari syndrome; portal vein; venous thrombosis; prothrombin; mutation; review
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号